Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down

Abbott is projecting strong growth for Synthroid in 2002 despite the phase-down of distribution required during FDA review of the NDA for the levothyroxine product

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet